FDA MDR rule speaks plainly
This article was originally published in The Gray Sheet
Executive Summary
Direct final rule to translate FDA's medical device reporting rule into plain language will become effective July 13, FDA confirms. The agency received 16 comments, including letters from NEMA and AdvaMed, urging it to make revisions to the MDR reg before moving forward with the final rule (1"The Gray Sheet" May 30, 2005, p. 6). However, FDA has decided to implement the plain language modifications as initially proposed in February. FDA "did not receive any significant comment on the plain language revisions," FDA explains in the Federal Register notice...
You may also be interested in...
MDR Revision Is More Restrictive, Misses Opportunities – NEMA, AdvaMed
FDA should withdraw its medical device reporting direct final rule and "proceed with the usual procedures for notice and comment on the companion proposed rule," NEMA asserts in a May 12 FDL-1letter to the agency
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.